The short version of anti-doping fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-12-19 and is reviewed periodically as new material appears.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
==== TP0453 ==== TP0453 is a 287 amino acid protein associated with the inner membrane of the microbe's outer membrane. This protein lacks the extensive beta sheet structure that is characteristic of other membrane proteins, and does not traverse the outer membrane. This protein's function has been hypothesized to be involved with control of nutrient uptake.
== References == Albert Szent-Györgyi et al.: The role of chemistry in the evolution of molecular medicine. Szeged, 2004, pp. 694–695. A Magyar Tudományos Akadémia tagjai 1825–2002 II [Members of the Hungarian Academy of Sciences 1825-2002]. Budapest, 2003, pp. 676–677.
López-Muñoz, F.; Ucha-Udabe, R.; Alamo, C. (2005). "The history of barbiturates a century after their clinical introduction". Neuropsychiatric Disease and Treatment. 1 (4): 329–343. PMC 2424120. PMID 18568113.
== Medical uses == Tafasitamab, in combination with lenalidomide, is indicated for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma. In the EU, tafasitamab (Minjuvi) is indicated in combination with lenalidomide followed by tafasitamab monotherapy for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplant. In June 2025, the US Food and Drug Administration (FDA) expanded the indication for tafasitamab, in combination with lenalidomide and rituximab, for adults with relapsed or refractory follicular lymphoma.
Sources: en.wikipedia.org
L'Atalante by Jean Vigo (1934) Le Quai des brumes by Marcel Carné (1938) Un homme marche dans la ville by Marcello Pagliero took place in the port and the Saint-François district after the Second World War. Ce qu'ils imaginent by Anne Théron (2004) The city has also hosted the filming of several comedies such as:
== Limitations == Despite its aforementioned advantages as a specialized tool, the B1H system does have some drawbacks. First, the B1H selection system is limited in its capacity to determine the binding specificities of transcription factors with lengthy binding sites. This arises from the fact that the number of randomized “prey” clones required to represent all possible target sequences increases exponentially with the number of nucleotides in that target sequence. Second, some eukaryotic factors may not express or fold efficiently in the bacterial system, attributed to differing regulatory networks and transcriptional machinery. Hence when working with DNA-binding proteins of eukaryotic origin, a yeast-based hybrid system may be beneficial. Third, the B1H system may not be ideally suited for transcription factors that recognize binding sites with low affinity. The logic here is that competition created by binding sites elsewhere in the bacterial genome may limit the signal that can be realized from a single binding site that is present upstream of the reporter.
Bradycardia, junctional rhythms and QRS widening are particularly associated with increased risk of adverse outcomes The serum potassium concentration at which electrocardiographic changes develop is somewhat variable. Although the factors influencing the effect of serum potassium levels on cardiac electrophysiology are not entirely understood, the concentrations of other electrolytes, as well as levels of catecholamines, play a major role. ECG findings are not a reliable finding in hyperkalemia. In a retrospective review, blinded cardiologists documented peaked T-waves in only 3 of 90 ECGs with hyperkalemia. Sensitivity of peaked-Ts for hyperkalemia ranged from 0.18 to 0.52, depending on the criteria for peak-T waves.
The coagulation cascade of secondary hemostasis has two initial pathways which lead to fibrin formation. These are the contact activation pathway (also known as the intrinsic pathway), and the tissue factor pathway (also known as the extrinsic pathway), which both lead to the same fundamental reactions that produce fibrin. It was previously thought that the two pathways of coagulation cascade were of equal importance, but it is now known that the primary pathway for the initiation of blood coagulation is the tissue factor (extrinsic) pathway. The pathways are a series of reactions, in which a zymogen (inactive enzyme precursor) of a serine protease and its glycoprotein co-factor are activated to become active components that then catalyze the next reaction in the cascade, ultimately resulting in cross-linked fibrin. Coagulation factors are generally indicated by Roman numerals, with a lowercase a appended to indicate an active form. The coagulation factors are generally enzymes called serine proteases, which act by cleaving downstream proteins. The exceptions are tissue factor, FIV, FV, FVIII, FXIII. Tissue factor, FV, and FVIII are glycoproteins; Factor IV is a calcium ion; and Factor XIII is a transglutaminase. The coagulation factors circulate as inactive zymogens. The coagulation cascade is therefore classically divided into three pathways. The tissue factor and contact activation pathways both activate the "final common pathway" of factor X, thrombin and fibrin.
== Pathology == When the sulcular depth is chronically in excess of three millimeters, regular home care may be insufficient to properly cleanse the full depth of the sulcus, allowing food debris and microbes to accumulate, forming dental biofilm. This poses a danger to the periodontal ligament (PDL) fibers that attach the gingiva to the tooth. If accumulated microbes remain undisturbed in a sulcus for an extended period of time, they will penetrate and ultimately destroy the delicate soft tissue and periodontal attachment fibers. If left untreated, this process may lead to a deepening of the sulcus, recession, destruction of the periodontium, including the bony tooth socket, tooth mobility, and tooth loss. A periodontal pocket is a dental term indicating the presence of an abnormally deepened gingival sulcus.
Sources: en.wikipedia.org
== Materials == Stainless steels, such as Type 304L and 316L, are used extensively in the fabrication of water treatment plants due to their corrosion resistance to water and to the corrosivity of chlorination used for disinfection.
== Canada, United States of America, Europe == Abdul Rahman Ibrahima Sori (c. 1762 – 1829) – Son of Ibrahim Sori Mawdo of Futa-Jallon. Enslaved in Natchez, Mississippi but freed and repatriated to Liberia. Alhaji Mohammed Ayuba Suleiman Diallo (also known as Job ben Solomon) – Trader, then slave. Freed and repatriated to his homeland in Boundou, Senegal Bill Hamid Diaryatou Bah - French female activist. Moussa Diallo Elhadj - Senator, Belgian Senate. Philippe Diallo - President of French Football Federation Nafissatou Thiam - Three time heptathlon Olympic Gold Medalist, Hepthathlon World Record Holder. Satou Sabally - German-American Female Basketballer, Three time WNBA All star, WNBA Most Improved Player (2023), All-WNBA First Team (2023). Nyara Sabally - German Female Basketballer, WNBA champion 2024. Abou Diaby - former Arsenal and French National team Player. Romane Dicko - Two time single judo olympics bronze medalist, two time mixed olympics Gold medalist. Ousmane Dembélé - french national team player, Ballon D'or 2025 Elladj Baldé - Canadian figure skater. He won the 2015 Nebelhorn Trophy, an ISU Challenger Series event. He is the 2008 Canadian Junior champion. Boris Diaw - French basketball player Alexander Bah - Danish football player Djibril Sidibé (footballer, born 1992) - French World cup winner.
On 30 June 2018, Charlie Rowley and Dawn Sturgess were found unconscious at a house in Amesbury, Wiltshire, about eight miles from the Salisbury poisoning site. On 4 July 2018, police said that the pair had been poisoned with the same nerve agent as ex-Russian spy Sergei Skripal. On 8 July 2018, Sturgess died as a result of the poisoning. Rowley regained consciousness and began recovering in hospital. He told his brother Matthew the nerve agent had been in a small perfume or aftershave bottle, which they had found in a park about nine days before spraying themselves with it. The police later closed and fingertip-searched Queen Elizabeth Gardens in Salisbury.
== Tetra Brik Aseptic == The Tetra Brik Aseptic came onto the market in 1969 and soon became Tetra Pak's flagship package. Due to the aseptic technology, there was no longer a need for a cold chain, which made the package economical and suitable for warmer climates, something that greatly expanded potential markets.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.